Is Sermorelin Legal in Florida? How to Access It Legally
HealthRX.com
Sermorelin has no FDA approval, so Florida supply is compounded
Key numbers
- 30 micrograms per kgPediatric dose used in a study of children with growth hormone deficiency; not an approved doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 0.5 mgStudy dose per injection in healthy older men; a study dose, not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 8.0 cm/yrHeight velocity at 6 months in children with growth hormone deficiency, up from 4.1 cm/yr at baselineSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Sermorelin
At a glance
- FDA-approved sermorelin / None; Geref approvals withdrawn June 18, 2009 [1]
- Sold today / Compounded, not FDA-reviewed [2]
- FDA safety-risk bulk list / Sermorelin is not on it [3]
- FDA outsourcing-facility list / Category 1, under evaluation [4]
- FDA list for state-licensed pharmacies / Sermorelin in no category [5]
What is sermorelin's FDA status?
Sermorelin acetate reached the US market as Geref under two applications: NDA 019863, a 0.05 mg/ampule diagnostic product approved December 28, 1990, and NDA 020443, 0.5 mg and 1 mg vials for idiopathic growth hormone deficiency in children with growth failure, approved September 26, 1997 [1]. Geref was never approved for adults, anti-aging, weight loss or athletic performance [1].
The manufacturer discontinued both products in 2008 and asked FDA to withdraw the applications; FDA withdrew both approvals effective June 18, 2009, and in March 2013 determined that Geref had not been withdrawn from sale for reasons of safety or effectiveness [1][6].
What is sold today?
Every sermorelin product sold in the US now is compounded, not FDA-approved, and FDA does not review a compounded drug's safety, effectiveness or quality before it is marketed [2]. Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone, not growth hormone itself; it stimulates the pituitary to release the body's own growth hormone [7].
Where it sits on FDA's compounding lists
- FDA's list of bulk substances that may present significant safety risks, content dated 04/22/2026, does not include sermorelin [3].
- FDA's list of nominated bulk substances for outsourcing facilities, updated March 21, 2025, places sermorelin acetate in category 1, under evaluation, marked as a component of FDA-approved drugs [4].
- FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, places sermorelin in no category [5].
Category 1 means under evaluation, not approval [4].
What about Florida?
FDA's lists and the Geref approval history are federal. They do not state what Florida law requires for prescribing or compounding sermorelin. What the federal record does establish is that a sermorelin prescription filled in Florida would be for a compounded product FDA has not reviewed [2]. See HealthRX.com's sermorelin page for the product.
Questions worth asking
What doses were used in studies?
No sermorelin product is currently approved, so there is no approved dose [1]. The pediatric program used 30 micrograms per kg once daily subcutaneously at bedtime; in a one-year open-label study of 110 previously untreated prepubertal children with growth hormone deficiency (86 evaluable), height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months [8]. In a short physiology study of 10 healthy older men (mean age 68), each man received 0.5 mg and 1 mg subcutaneously twice daily for 14 days per dose, in random order, with 14 days between treatments [9]. These are study doses, not recommended doses.
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
FDA recalls of sermorelin products by Florida firms, 2012 to 2025
11 recall events in FDA records that name sermorelin and were started by firms in Florida, from 2012 to 2025. Each links to the record itself.
6 of 11 events shown
GenoGenix LLC: recall of one sermorelin product
Class II recall, now ongoing. Reason FDA lists: Lack of Assurance of Sterility.
Olympia Compounding Pharmacy dba Olympia Pharmacy: recall of one sermorelin product (2022-05-09)
Class II recall, now completed. Reason FDA lists: Lack of assurance of sterility.
Olympia Compounding Pharmacy dba Olympia Pharmacy: recall of one sermorelin product (2022-04)
Class II recall, now terminated. Reason FDA lists: CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated.
Olympia Compounding Pharmacy dba Olympia Pharmacy: recall of one sermorelin product
Class II recall, now terminated. Reason FDA lists: Sub Potent.
KRS Global Biotechnology, Inc: recall of 8 sermorelin products
Class II recall, now terminated. Reason FDA lists: Lack of Assurance of Sterility.
Promise Pharmacy, LLC: recall of 6 sermorelin products
Class II recall, now terminated. Reason FDA lists: Lack of sterility assurance.
KRS Global Biotechnology, Inc: recall of 4 sermorelin products
Class II recall, now terminated. Reason FDA lists: Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredient used to make final product.
Tri-Coast Pharmacy: recall of 8 sermorelin products
Class II recall, now ongoing. Reason FDA lists: Lack of Assurance of Sterility.
Wells Pharmacy Network LLC: recall of 12 sermorelin products
Class II recall, now terminated. Reason FDA lists: Lack of Assurance of Sterility.
Lowlite Investments, Inc. D/B/A Olympia Pharmacy: recall of one sermorelin product
Class II recall, now ongoing. Reason FDA lists: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.
Franck's Lab Inc., d.b.a. Franck's Compounding Lab: recall of one sermorelin product
Class II recall, now terminated. Reason FDA lists: Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.
Frequently asked questions
Was sermorelin ever FDA-approved?
Was Geref pulled for safety reasons?
Is sermorelin allowed in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How can you get prescribed sermorelin?
Florida law on prescribing sermorelin is not stated in the federal facts. Any sermorelin sold in Florida is compounded, so a prescription filled there would be for a compounded product FDA has not reviewed for safety, effectiveness or quality. No sermorelin product is currently FDA-approved.
Does sermorelin really work?
Sermorelin's benefit in adults is not established. Geref was never approved for adults, anti-aging, weight loss or athletic performance. In a one-year open-label study of 110 previously untreated prepubertal children with growth hormone deficiency (86 evaluable), height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months.
References
Show all 11 referencesHide references
- Federal Register :: Request Access.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- World Anti-Doping Agency.
- World Anti-Doping Agency.